Kiniksa Pharmaceuticals/$KNSA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Ticker
$KNSA
Sector
Primary listing
Employees
315
Headquarters
Website
KNSA Metrics
BasicAdvanced
$3.1B
86.37
$0.47
0.03
-
Price and volume
Market cap
$3.1B
Beta
0.03
52-week high
$42.05
52-week low
$17.82
Average daily volume
468K
Financial strength
Current ratio
3.848
Quick ratio
3.268
Long term debt to equity
1.312
Total debt to equity
1.815
Profitability
EBITDA (TTM)
39.641
Gross margin (TTM)
52.79%
Net profit margin (TTM)
6.01%
Operating margin (TTM)
6.38%
Effective tax rate (TTM)
26.13%
Revenue per employee (TTM)
$1,900,000
Management effectiveness
Return on assets (TTM)
3.76%
Return on equity (TTM)
7.39%
Valuation
Price to earnings (TTM)
86.369
Price to revenue (TTM)
4.941
Price to book
5.68
Price to tangible book (TTM)
5.85
Price to free cash flow (TTM)
29.045
Free cash flow yield (TTM)
3.44%
Free cash flow per share (TTM)
1.388
Growth
Revenue change (TTM)
55.68%
Earnings per share change (TTM)
-465.19%
3-year revenue growth (CAGR)
50.04%
3-year earnings per share growth (CAGR)
-38.92%
What the Analysts think about KNSA
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
KNSA Financial Performance
Revenues and expenses
KNSA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kiniksa Pharmaceuticals stock?
Kiniksa Pharmaceuticals (KNSA) has a market cap of $3.1B as of November 16, 2025.
What is the P/E ratio for Kiniksa Pharmaceuticals stock?
The price to earnings (P/E) ratio for Kiniksa Pharmaceuticals (KNSA) stock is 86.37 as of November 16, 2025.
Does Kiniksa Pharmaceuticals stock pay dividends?
No, Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders as of November 16, 2025.
When is the next Kiniksa Pharmaceuticals dividend payment date?
Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals (KNSA) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.